BirchBioMed
BirchBioMed is a clinical-stage biopharmaceutical company focused on developing innovative treatments for high unmet medical needs such as organ fibrosis, scarring, skin disorders, and autoimmune conditions like Type 1 Diabetes and Alopecia Areata. Leveraging exclusive licenses from the University of British Columbia for FS2 (Kynurenic Acid/KynA) and AI-001 (KynA with Antigen Presenting Cells therapy), the company aims to provide revolutionary treatments, including topical creams for scars and systemic therapies for organ fibrosis and autoimmune diseases. Their FS2 topical cream has shown superiority over market leaders in treating keloid scars, and they plan to partner this for global outreach. The company is also positioning for a public listing and targets a Total Addressable Market of $96.9 billion.
BirchBioMed
BirchBioMed is a clinical-stage biopharmaceutical company focused on developing innovative treatments for high unmet medical needs such as organ fibrosis, scarring, skin disorders, and autoimmune conditions like Type 1 Diabetes and Alopecia Areata. Leveraging exclusive licenses from the University of British Columbia for FS2 (Kynurenic Acid/KynA) and AI-001 (KynA with Antigen Presenting Cells therapy), the company aims to provide revolutionary treatments, including topical creams for scars and systemic therapies for organ fibrosis and autoimmune diseases. Their FS2 topical cream has shown superiority over market leaders in treating keloid scars, and they plan to partner this for global outreach. The company is also positioning for a public listing and targets a Total Addressable Market of $96.9 billion.